Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Melanoma

  Free Subscription


Articles published in Nat Med

Retrieve available abstracts of 46 articles:
HTML format



Single Articles


    February 2024
  1. BJORK JR, Bolte LA, Maltez Thomas A, Lee KA, et al
    Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
    Nat Med. 2024 Feb 16. doi: 10.1038/s41591-024-02803.
    PubMed     Abstract available


    January 2024
  2. O'LEARY K
    Personalized mRNA vaccine boosts melanoma immunotherapy.
    Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
    PubMed    


  3. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2024 Jan 4. doi: 10.1038/s41591-023-02775.
    PubMed    


    November 2023
  4. FRATERMAN I, Reijers ILM, Dimitriadis P, Broeks A, et al
    Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02631.
    PubMed     Abstract available


  5. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02650.
    PubMed    


  6. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02661.
    PubMed    


    October 2023
  7. KIRKWOOD J, Del Vecchio M, Weber J, Hoeller C, et al
    Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02583.
    PubMed     Abstract available


    August 2023
  8. VANDERWALDE A, Bellasea SL, Kendra KL, Khushalani NI, et al
    Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
    Nat Med. 2023 Aug 17. doi: 10.1038/s41591-023-02498.
    PubMed     Abstract available


  9. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    PubMed    


  10. BARATA C, Rotemberg V, Codella NCF, Tschandl P, et al
    A reinforcement learning model for AI-based decision support in skin cancer.
    Nat Med. 2023;29:1941-1946.
    PubMed     Abstract available


    July 2023
  11. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02453.
    PubMed     Abstract available


  12. BRASTIANOS PK, Kim AE, Giobbie-Hurder A, Lee EQ, et al
    Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
    Nat Med. 2023;29:1728-1737.
    PubMed     Abstract available


    May 2023
  13. GARBE C, Dummer R, Amaral T, Amaria RN, et al
    Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
    Nat Med. 2023 May 16. doi: 10.1038/s41591-023-02336.
    PubMed    


    April 2023
  14. LIU S, Dharanipragada P, Lomeli SH, Wang Y, et al
    Multi-organ landscape of therapy-resistant melanoma.
    Nat Med. 2023 Apr 27. doi: 10.1038/s41591-023-02304.
    PubMed     Abstract available


  15. GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al
    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
    Nat Med. 2023;29:898-905.
    PubMed     Abstract available


    March 2023
  16. O'LEARY K
    Earlier appears better for immunotherapy in melanoma.
    Nat Med. 2023 Mar 16. doi: 10.1038/d41591-023-00028.
    PubMed    


  17. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    PubMed     Abstract available


    February 2023
  18. SOLIMAN H, Hogue D, Han H, Mooney B, et al
    Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.
    Nat Med. 2023;29:450-457.
    PubMed     Abstract available


  19. TIAN J, Chen JH, Chao SX, Pelka K, et al
    Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial.
    Nat Med. 2023;29:458-466.
    PubMed     Abstract available


  20. NIKNAFS N, Balan A, Cherry C, Hummelink K, et al
    Persistent mutation burden drives sustained anti-tumor immune responses.
    Nat Med. 2023;29:440-449.
    PubMed     Abstract available


    December 2022
  21. TAYLOR CA, Watson RA, Tong O, Ye W, et al
    IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
    Nat Med. 2022 Dec 16. doi: 10.1038/s41591-022-02095.
    PubMed     Abstract available


    November 2022
  22. SIMPSON RC, Shanahan ER, Batten M, Reijers ILM, et al
    Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.
    Nat Med. 2022;28:2344-2352.
    PubMed     Abstract available


    October 2022
  23. CARVAJAL RD, Butler MO, Shoushtari AN, Hassel JC, et al
    Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02015.
    PubMed     Abstract available


    July 2022
  24. ZHANG Y, Trang V, Palmer DC, Kishton RJ, et al
    A T cell resilience model associated with response to immunotherapy in multiple tumor types.
    Nat Med. 2022;28:1421-1431.
    PubMed     Abstract available


    June 2022
  25. REIJERS ILM, Menzies AM, van Akkooi ACJ, Versluis JM, et al
    Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
    Nat Med. 2022 Jun 5. pii: 10.1038/s41591-022-01851.
    PubMed     Abstract available


    April 2022
  26. MONTEIRO C, Miarka L, Perea-Garcia M, Priego N, et al
    Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.
    Nat Med. 2022;28:752-765.
    PubMed     Abstract available


    March 2022
  27. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2022 Mar 8. pii: 10.1038/s41591-022-01771.
    PubMed    


    February 2022
  28. MCCULLOCH JA, Davar D, Rodrigues RR, Badger JH, et al
    Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.
    Nat Med. 2022 Feb 28. pii: 10.1038/s41591-022-01698.
    PubMed     Abstract available


  29. LEE KA, Thomas AM, Bolte LA, Bjork JR, et al
    Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
    Nat Med. 2022 Feb 28. pii: 10.1038/s41591-022-01695.
    PubMed     Abstract available


    January 2022
  30. LOZANO AX, Chaudhuri AA, Nene A, Bacchiocchi A, et al
    T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
    Nat Med. 2022 Jan 13. pii: 10.1038/s41591-021-01623.
    PubMed     Abstract available


    December 2021
  31. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2021;27:2212-2223.
    PubMed     Abstract available


  32. O'LEARY K
    FMT for patients with cancer.
    Nat Med. 2021;27:2057.
    PubMed    


    October 2021
  33. DUMMER R, Gyorki DE, Hyngstrom J, Berger AC, et al
    Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01510.
    PubMed     Abstract available


    August 2021
  34. ANDREWS MC, Duong CPM, Gopalakrishnan V, Iebba V, et al
    Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
    Nat Med. 2021;27:1432-1441.
    PubMed     Abstract available


    May 2021
  35. LIU D, Lin JR, Robitschek EJ, Kasumova GG, et al
    Evolution of delayed resistance to immunotherapy in a melanoma responder.
    Nat Med. 2021 May 3. pii: 10.1038/s41591-021-01331.
    PubMed     Abstract available


    February 2021
  36. MENZIES AM, Amaria RN, Rozeman EA, Huang AC, et al
    Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-020-01188.
    PubMed     Abstract available


  37. ROZEMAN EA, Hoefsmit EP, Reijers ILM, Saw RPM, et al
    Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-020-01211.
    PubMed     Abstract available


    January 2021
  38. PEREZ-GUIJARRO E, Yang HH, Araya RE, El Meskini R, et al
    Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
    Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01252.
    PubMed    


  39. HU Z, Leet DE, Allesoe RL, Oliveira G, et al
    Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
    Nat Med. 2021 Jan 21. pii: 10.1038/s41591-020-01206.
    PubMed     Abstract available


  40. STOWER H
    Microbiome transplant-induced response to immunotherapy.
    Nat Med. 2021;27:21.
    PubMed    


  41. YU J, Green MD, Li S, Sun Y, et al
    Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
    Nat Med. 2021;27:152-164.
    PubMed     Abstract available


    October 2020
  42. CEREZO-WALLIS D, Contreras-Alcalde M, Troule K, Catena X, et al
    Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.
    Nat Med. 2020 Oct 19. pii: 10.1038/s41591-020-1073.
    PubMed     Abstract available


  43. DUMMER R, Lebbe C, Atkinson V, Mandala M, et al
    Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Nat Med. 2020;26:1557-1563.
    PubMed     Abstract available


  44. ALGAZI AP, Othus M, Daud AI, Lo RS, et al
    Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
    Nat Med. 2020;26:1564-1568.
    PubMed     Abstract available


  45. RYLL B
    From good to great: what patients can do for your medical research.
    Nat Med. 2020;26:1508.
    PubMed    


    July 2020
  46. ALLEN BM, Hiam KJ, Burnett CE, Venida A, et al
    Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.
    Nat Med. 2020;26:1125-1134.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.